No Data
Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients With Cirrhotic Portal Hypertension Caused by MASH
12 Health Care Stocks Moving In Friday's Pre-Market Session
Catalyst Watch: Labor Pains for Amazon & Starbucks, Nasdaq Call-up for MicroStrategy and Pony AI Ratings
Galectin Therapeutics Shares Drop 54% After Treatment Misses Trial Endpoint
Top Midday Decliners
Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher